Back to All Events

Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee (ORUDAC)

  • IQVIA Solutions Denmark A/S Denmark (map)

On 9th and 10th May 2023, the Nonprescription Drugs Advisory Committee and the Obstetrics, Reproductive and Urologic Drugs Advisory Committee will discuss sNDA for OPILL (norgestrel) tablet, submitted by Laboratoire HRA Pharma for nonprescription use to prevent Pregnancy.

Source:: https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-9-10-2023-joint-meeting-nonprescription-drugs-advisory-committee-and-obstetrics-reproductive-and
Earlier Event: April 28
Oncologic Drugs Advisory Committee (OADC)
Later Event: May 12
Cellular, Tissue, and Gene Therapies Advisory Committee